EHA 2021 | Phase II trial of bomedemstat for advanced myelofibrosis
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, shares updated data from an ongoing, multi-national, open label, 24-week Phase II study (NCT03136185) of bomedemstat for advanced myelofibrosis. In this study, patients with myelofibrosis received bomedemstat once daily. After a median duration of treatment of 12 weeks, multiple objectives in evaluable patients were assessed, including total symptoms score, reduction in spleen volume from baseline, hemoglobin levels and fibrosis score. Dr Gill gives an overview of the key findings from the study so far, and comments on bomedemstat’s safety profile in this cohort, as well as comparing outcomes with bomedemstat to outcomes with other therapies, such as JAK inhibitors. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
